Bio-Techne Corp

-0.86 (-1.08%)
5:00:00 PM EDT: $79.29 +0.86 (+1.10%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)12.21B
Current PE44.93
Forward PE 39.41
2yr Forward PE 33.95
See more stats
Estimates Current Quarter
Revenue$308.73 Million
Adjusted EPS$0.55
See more estimates
10-Day MA$81.29
50-Day MA$80.92
200-Day MA$79.03
See more pivots

Bio-Techne Corp Stock, NASDAQ:TECH

614 McKinley Place NE, Minneapolis, Minnesota 55413-2610
United States of America
Phone: +1.612.379.8854
Number of Employees: 3000


Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.